Demographics

no previous CAD

previous CAD

p

 

n=1452

n=1049

 
Age 66.7±10.8 69.5±10.5 <0.0001
Height 170.6±9.6 171.3±8.7 0.06
Body weight 81.9±16.8 81.97±14.99 0.86
Abdomen circumference 98.5±13.5 99.6±13.6 0.13
BMI 28.1±4.9 27.9±4.6 0.54
Male Sex 772 (53.8%) 767 (73.8%) <0.0001
Risk factors/concomitant diseases
Hypertension 1015 (69.9%) 817 (77.9%) <0.0001
Dyslipidemia 627 (43.2%) 688 (65.6%) <0.0001
Diabetes mellitus 284 (19.6%) 292 (27.8%) <0.0001
COPD 116 (8.0%) 99 (9.4%) 0.219
Renal impairement 60 (4.1%) 80 (7.6%) <0.0001
PAD 64 (4.4%) 100 (9.5%) <0.0001
Previous myocardial infarction 0 (0%) 311 (29.6%) <0.0001
Prior Stroke 42 (2.9%) 53 (5.1%) 0.006
Smoking 415 (28.6%) 303 (28.9%) 0.893

Pack years (smokers only)

29.2±23.0 30.53±32.1 0.6
Symptoms
Classic AP 598 (41.2%) 541 (51.6%) <0.0001
Atypical AP 470 (32.4%) 309 (29.5%) 0.126
Exertionaldyspnea 632 (43.5%) 381 (36.3%) <0.0001
Number of AP per week 3.1±4 3.6±4.2 0.003
Number of NTG-intake per week 0.64±1.9 1.7±3.4 <0.0001
Stress test (performed)      
Bicycle-Stress ECG 954 (65.7%) 646 (61.6%) 0.035
Stress echocardiography 123 (8.5%) 76 (7.2%) 0.295
Scintigraphy 115 (7.9%) 86 (8.2%) 0.823
cMR 20 (1.4%) 11 (1.0%) 0.584
Any positive stress test 567 (39.0%) 382 (36.4%) 0.182
Medical therapy
Platelet inhibitors 664 (45.7%) 827 (78.8%) <0.0001
Beta-blockers 731 (50.3%9 785 (74.8%) <0.0001
ACE-inhibitors 535 (36.8%) 530 (50.5%) <0.0001
AT1-receptor blockers 289 (19.9%) 243 (23.2%) 0.053
Calcium antagonists 260 (17.9%) 237 (22.6%) 0.004
Nitrates
Long-acting 71 (4.9%) 198 (18.9%) <0.0001
Short-acting 111 (7.6%) 194 (18.5%) <0.0001
NTG spray or sublingugal capsule 120 (8.2%) 210 (20%) <0.0001
Statins 406 (28%) 762 (72.6%) <0.0001
CAD (new or progression of known disease) 240 (16.5%) 892 (85%) <0.0001
Table 1: Demographics of all patients included in this study. BMI: Body Mass Index; COPD: Chronic Obstructive Pulmonary Disease.